Viatris Inc has disclosed a transaction involving deferred stock units (DSUs) by board member David S. Simmons. This filing, made on October 2, 2026, highlights the company’s strategy to align director compensation with shareholder interests.
Viatris, categorized under SIC 2834 for Pharmaceutical Preparations, is a large accelerated filer listed on the Nasdaq under the ticker VTRS. The company was formed through the merger of Mylan and Upjohn, a division of Pfizer, and has been active in the pharmaceutical industry since its inception.
According to the SEC filing, Simmons was granted 2,117 deferred stock units on September 30, 2026. This grant was made as part of his election to receive payment of quarterly non-employee director fees in DSUs instead of cash. The transaction was valued at $17.72 per share, which was the closing price of Viatris common stock on that date. The DSUs are fully vested and will convert into shares of common stock upon certain events, such as termination of service or a change in control.
The filing also notes that Simmons holds additional dividend equivalent DSUs that accrued from previously granted DSUs. These dividend equivalents are designed to align the interests of directors with those of shareholders, as they vest on the same schedule as the underlying DSUs.
This update may impact how other companies in the pharmaceutical preparations industry structure their director compensation and incentive programs. As firms strive to align compensation with shareholder interests, Viatris's approach could serve as a model for others in the sector.
Looking ahead, it remains unclear what further actions Viatris may take regarding its executive compensation strategy. The filing does not specify any upcoming votes or additional filings related to this matter.